CVM - CEL-SCI Corporation

NYSE American - NYSE American Delayed Price. Currency in USD
+0.26 (+3.88%)
At close: 4:00PM EDT

7.10 +0.15 (2.16%)
Pre-Market: 8:00AM EDT

Stock chart is not supported by your current browser
Previous Close6.70
Bid0.00 x 1000
Ask0.00 x 800
Day's Range6.52 - 6.96
52 Week Range0.82 - 7.50
Avg. Volume604,624
Market Cap229.912M
Beta (3Y Monthly)2.71
PE Ratio (TTM)N/A
EPS (TTM)-1.19
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date1996-08-28
1y Target Est14.00
Trade prices are not sourced from all markets
  • Business Wire28 days ago

    CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study

    CEL-SCI Corporation (NYSE American: CVM) announced today that the Independent Data Monitoring Committee (IDMC) for the Company's pivotal Phase 3 head and neck cancer study of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) has completed its recent review of the Phase 3 study data. The data from all 928 enrolled patients were provided to the IDMC by the clinical research organization (CRO) responsible for data management of this Phase 3 study.

  • GlobeNewswirelast month

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of CEL-SCI Corporation

    NEW YORK, March 26, 2019 -- Levi & Korsinsky announces it has commenced an investigation of CEL-SCI Corporation (NYSEAMERICAN: CVM) concerning possible breaches of.

  • Business Wirelast month

    CEL-SCI Corporation Releases Letter to Shareholders

    The enrollment of 928 patients in our Phase 3 clinical trial of Advanced Primary (just diagnosed and not yet treated) Head and Neck Cancer was completed in September of 2016. For the study to end we have to wait for 298 events (deaths) in the two main groups to show a survival benefit. Based on published survival data, we had already expected to have reached the 298 events.

  • Business Wire2 months ago

    CEL-SCI Selected by National Institutes of Health to Showcase Its LEAPS Technology at BIO International Convention

    CEL-SCI Corporation (NYSE American: CVM) today announced it has been selected by the U.S. National Institutes of Health (NIH) for sponsorship to exhibit and showcase its presentation for its LEAPS technology at the BIO International Convention, to be held June 3-6, 2019 in Philadelphia. LEAPS, which is currently being developed as a therapeutic vaccine for rheumatoid arthritis under a $1.5 million SBIR/STTR grant from the NIH, will be featured at the convention’s Innovation Zone, a turn-key exhibit space dedicated to showcasing select NIH SBIR/STTR awardees.

  • Business Wire2 months ago

    CEL-SCI’s Scientific Article on Vaccines for Autoimmune Disease Published in Journal of Clinical & Cellular Immunology

    CEL-SCI Corporation (NYSE American:CVM) today announced the Journal of Clinical & Cellular Immunology has published an article titled, “Why Don’t We Have a Vaccine Against Autoimmune Diseases?” co-written by Dr. Ken Rosenthal of Roseman University College of Medicine, and CEL-SCI’s Roy Carambula, Research Associate and Daniel Zimmerman Ph.D., Senior Vice President of Cellular Immunology.

  • Zacks Small Cap Research2 months ago

    CVM: Clinical Trials Update

    This assessment is based on historical event rates which suggests the final event will take place in the next few months. In CEL-SCI Corporation’s (CVM) a recent update to, we noticed that the anticipated completion was changed from December 2017 to December 2020. Management stated that the new anticipated completion date should read September 2019.

  • Associated Press2 months ago

    Cel-Sci: Fiscal 1Q Earnings Snapshot

    On a per-share basis, the Vienna, Virginia-based company said it had profit of 2 cents. Losses, adjusted for non-recurring gains, were 17 cents per share. The cancer immunotherapy company posted revenue ...

  • Business Wire2 months ago

    CEL-SCI Corporation Reports First Quarter Fiscal 2019 Financial Results

    CEL-SCI Corporation today reported financial results for the quarter ended December 31, 2018.

  • Business Wire3 months ago

    CEL-SCI to Present at 2019 BIO CEO & Investor Conference

    CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, announced today that Geert Kersten, Chief Executive Officer, will be presenting at the 2019 BIO CEO & Investor Conference in New York, NY on Monday, February 11, 2018 at 2:00 p.m. A live audio webcast of the presentation and replay will be available on CEL-SCI's website at Now in its 21st year, the BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly traded and select private biotech companies.

  • Zacks Small Cap Research3 months ago

    CVM: CEL-SCI: Advancing with an Intent to Cure

    We are initiating coverage of CEL-SCI Corporation (CVM) with a $14.00 price target based on our estimates for a 2021 US and 2022 EU launch of lead compound Multikine in squamous cell carcinoma of the head and neck (SCCHN). The clinical-stage company is developing this biological product which contains multiple cytokines to enable the body to mount an anti-tumor immune response. The biologic is being developed as a first line therapy that will be administered to newly diagnosed, but not yet treated, head and neck cancer patients prior to their receiving standard of care (SOC), which includes surgery, chemotherapy and radiotherapy.

  • ACCESSWIRE3 months ago

    LD Micro Welcomes Nearly 1,000 Companies to the LD Micro Index

    LOS ANGELES, CA / ACCESSWIRE / February 1, 2019 / LD Micro is pleased to announce that the LD Micro Index is being reconstituted as of February 1, 2019. Again. We have always held the belief that our industry ...

  • Business Wire3 months ago

    U.S. Patent Office Issues CEL-SCI Two Patents for Its LEAPS Vaccine Platform Technology

    CEL-SCI Corporation (NYSE American: CVM) today announced the U.S. Patent and Trademark Office has issued two new U.S. patents for the Company’s LEAPS platform technology. CEL-SCI’s LEAPS inventions relate to methods for diagnosing, preventing, and treating disease by generating or modulating the immune response through the use of specific peptides.

  • Business Wire3 months ago

    CEL-SCI Regains Full Listing Compliance with NYSE American

    CEL-SCI Corporation (NYSE American: CVM) today announced that it has received notification from the staff of the NYSE American, its current listing exchange, that the Company is now considered in full compliance with the continued listing requirements. The Company previously received notice on July 12, 2018, indicating that the Company was not in compliance with Section 1003(a)(i), Section 1003(a)(ii) and Section 1003(a)(iii) of the listing requirements of the Exchange since it reported a stockholders’ equity deficit as of March 31, 2018 and had net losses in its 5 most recent fiscal years ended September 30, 2017.

  • Business Wire4 months ago

    CEL-SCI Reports Fiscal 2018 Financial Results and Clinical & Corporate Developments

    VIENNA, Va.-- -- CEL-SCI Corporation reported financial results for the fiscal year ended September 30, 2018. The Company also reported key clinical and corporate developments achieved during fiscal 2018. Clinical and Corporate Developments included: CEL-SCI’s Phase 3 head and neck cancer study continued to follow all 928 patients. The Company is now awaiting final study results. All that remains to ...

  • GlobeNewswire5 months ago

    Investor Expectations to Drive Momentum within Cel-Sci, DGSE Companies, Veracyte, China Pharma, Barnwell Industries, and Silvercrest Asset Management Group — Discovering Underlying Factors of Influence

    NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Business Wire6 months ago

    CEL-SCI Receives about $8 Million from Warrant Exercises

    CEL-SCI Corporation (NYSE American: CVM) announced today it has received just under $8 million through the exercise of warrants to purchase shares of the Company's common stock during the past 3 months. As of October 22, 2018, CEL-SCI had 28,271,615 outstanding shares of common stock. "We have raised $20 million this year as we are nearing the date for the final data readout on our pivotal, global Phase 3 study in head and neck cancer," stated CEL-SCI's Chief Executive Officer Geert Kersten.

  • Zacks Small Cap Research6 months ago

    CVM: A New Solution in Head & Neck Cancer

    Nearing the end of its long running Phase III trial for squamous cell carcinoma of the head and neck (SCCHN), CEL-SCI (CVM) has experienced several recent catalysts that have returned attention and interest to their novel immuno-oncology program. In June an arbitrator promulgated a final ruling in favor of CEL-SCI’s claims that their previous contract research organization (CRO) had breached the contract related to the timely enrollment of the Multikine Phase III trial. Combined with the lifting of an FDA clinical hold in August 2017, the arbitration resolution allowed management’s primary focus to return to the Phase III primary head and neck cancer study.

  • Investopedia7 months ago

    Penny Stocks to Buy Using Technical Analysis for October 2018

    Blue chips led broad price action in September, lifting the S&P 500 and the Dow Jones Industrial Average to bull market highs while small cap indices such as the Russell 2000 pulled back in shallow declines. Penny and low-priced stocks held up well during the month despite this headwind, with traders scooping up junior energy plays in reaction to a surging crude oil market. Penny stock buyers have taken notice, lifting the shares of low-priced American oil and gas companies still reeling from the group's historic decline into 2016.

  • Business Wire7 months ago

    CEL-SCI Announces Warrants to Expire on October 11, 2018

    CEL-SCI Corporation (NYSE American: CVM) is advising the holders of its publicly traded warrants (NYSE American: CVM WS) that the warrants will expire and not be exercisable after 5:00 p.m., New York City time, on October 11, 2018. The NYSE has notified CEL-SCI that trading in the warrants on the NYSE American will be suspended after the close of business on October 8, 2018 to ensure all trades in the warrants settle in time to allow the purchasers of such warrants to exercise the warrants on or before the Expiration Date.

  • ACCESSWIRE7 months ago

    Deals Pile Up as Big Biotech Looks to Capitalize on the Growing Market

    HENDERSON, NV / ACCESSWIRE / September 20, 2018 / Small biotech companies have been receiving a ton of interest this year. Just last week, Boehringer Ingelheim's shopping spree continued with a €210m takeover of ViraTherapeutics, an oncolytic virus specialist it has been working with since 2016. Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, has recently announced an amendment to its Registration trial in ocular melanoma liver metastases, a disease that has shown resistance to the new immunotherapies.

  • Business Wire7 months ago

    CEL-SCI Receives $5.4 Million from Warrant Exercises

    CEL-SCI Corporation (NYSE American: CVM) announced today it has received $5,435,367 through the exercise of warrants to purchase shares of the Company's common stock during August through September 13, 2018. As of September 13, 2018, CEL-SCI had 27,351,324 outstanding shares of common stock. “We are pleased that warrant holders see the value of CEL-SCI’s common stock and have chosen to exercise their warrants.

  • Has Cel-Sci (CVM) Outpaced Other Medical Stocks This Year?
    Zacks8 months ago

    Has Cel-Sci (CVM) Outpaced Other Medical Stocks This Year?

    Is (CVM) Outperforming Other Medical Stocks This Year?

  • Business Wire8 months ago

    NIH Selects CEL-SCI’s LEAPS Rheumatoid Arthritis Vaccine for Commercialization Accelerator Program

    CEL-SCI Corporation (NYSE American: CVM) announced today that the National Institutes of Health (NIH) selected CEL-SCI and its LEAPS* rheumatoid arthritis vaccine candidate as a Small Business Innovation Research/Small Business Technology Transfer (SBIR/STTR) Commercialization Accelerator Program Phase II awardee for 2018-2019. LEAPS has been specifically selected by the NIH for the Commercialization Transition Track, which provides technical assistance to awardee companies to move NIH-funded technologies towards commercialization and market readiness.

  • ACCESSWIRE8 months ago

    Today's Research Reports on Trending Tickers: Sage Therapeutics and CEL-SCI

    NEW YORK, NY / ACCESSWIRE / August 22, 2018 / U.S. markets continue to edge higher on Tuesday as optimism over trade talks and upbeat earnings pushed equities into the green. Additionally, the Federal ...